Medical control of secondary hyperparathyroidism: We're not there yet  by Goodman, William G.
Kidney International, Vol. 65 (2004), pp. 335–336
EDITORIAL
Medical control of secondary hyperparathyroidism:
We’re not there yet
Secondary hyperparathyroidism (SHPT) is common in
patients with chronic kidney disease who require long-
term treatment with dialysis. Hyperplasia of the parathy-
roid glands is an integral component of the disorder,
contributing substantially to disease progression [1].
Medical management includes the use of phosphate-
binding medications to limit phosphorus retention and
control serum phosphorus levels, and the administration
of vitamin D sterols to diminish pre-pro-PTH gene tran-
scription and reduce parathyroid hormone (PTH) syn-
thesis. Results from short-term studies of several months’
duration indicate that such measures effectively lower
plasma PTH levels in many patients with SHPT. Much
less is known, however, about the impact of current ther-
apeutic strategies on long-term clinical outcomes.
Parathyroidectomy is required when the medical man-
agement of SHPT proves to be inadequate. The need for
surgical intervention thus provides a measure of the over-
all success or failure of medical therapy. In the current
issue of Kidney International, Kestenbaum et al [2] ex-
amined parathyroidectomy rates during the 1990s among
patients undergoing dialysis in the United States. Demo-
graphic data were obtained from the United States Renal
Data System (USRDS), and parathyroidectomy proce-
dures were determined from hospital records for patients
enrolled in the Medicare insurance program using event-
specific International Classification of Diseases-Clinical
Modification (ICD9-CM) codes [2]. Both crude parathy-
roidectomy rates and rates adjusted for temporal changes
in patient demographics for the end-stage kidney disease
population were calculated. Various risk factors associ-
ated with surgical parathyroidectomy were identified.
Younger age, female gender, white race, nondiabetic
causes of chronic kidney disease, peritoneal dialysis, and
greater duration of treatment with dialysis were all in-
dependently associated with relatively higher rates of
parathyroidectomy. Age and dialysis duration were par-
ticularly strong determinants. The results for age, gen-
der, race, and diabetes confirm earlier observations by
others [3] and thus serve to identify high-risk groups that
may benefit from additional efforts to optimize disease
management. The physiologic mechanisms that account
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for the development of more advanced disease in such
persons remain uncertain.
Overall, parathyroidectomy rates declined in the
United States during the second half of the 1990s [2].
Rates increased slightly between 1990 and 1995 but de-
creased thereafter and were approximately 30% lower by
the end of the decade, reaching a nadir in 1998. For each
year between 1996 and 1999, adjusted parathyroidectomy
rates were significantly lower than in 1990.
Such findings are encouraging in one respect and they
support the view that recent strategies for managing
SHPT have been effective in slowing disease progres-
sion and in reducing the need for surgical intervention.
The authors suggest, quite plausibly, that the introduc-
tion in 1990 of vitamin D preparations for intravenous
administration during hemodialysis could explain the re-
sults. More precisely, calcitriol was the only vitamin D
sterol approved for clinical use in the United States
to treat SHPT in patients with chronic kidney disease
during most of the interval encompassed by the report.
Although the widespread use of large oral doses of cal-
cium as a phosphate-binding agent might also affect dis-
ease progression, this therapeutic approach was adopted
some years earlier after the adverse effects of aluminum-
containing, phosphate-binding agents were recognized.
As such, it is unlikely to account for the observed decline
in parathyroidectomy rates after 1995.
Despite the potentially important role of vitamin D as
a modifier of disease progression, the results presented by
Kestenbaum et al indicate that parathyroidectomy rates
remained largely unchanged for the first 5 to 6 years after
intravenous calcitriol became available for use clinically
[2]. Rates declined only after 1995. Moreover, the down-
ward trend in the rate of surgical parathyroidectomy ends
in 1998, although the information needed to address this
issue adequately was not, by design, part of the data set
utilized for the study. It remains uncertain, therefore,
whether the widespread use of parenteral calcitriol ac-
counts for the observed decline in annual parathyroidec-
tomy rates during the latter portion of the 1990s.
Although recent results are encouraging, it is readily
apparent that the medical management of SHPT is only
partially effective in achieving favorable long-term clini-
cal outcomes and that there is an ongoing need for defini-
tive surgical intervention in many patients [2, 3]. Despite
the use of vitamin analogs, adjusted parathyroidectomy
rates are, on average, nearly six-fold greater in persons
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treated with dialysis for more than three years regard-
less of age, gender, race, dialysis modality, or cause of
kidney disease [2]. Previous reports indicate that both
dialysis duration and length of time with chronic kidney
disease before starting dialysis are major determinants
of the prevalence and severity of SHPT [3]. Such findings
are consistent with the view that tissue hyperplasia aris-
ing during the course of chronic kidney disease leads to
progressive enlargement of the parathyroid glands and
to worsening SHPT [1].
Disturbances in cell cycle regulation are an integral
component of parathyroid gland hyperplasia in chronic
kidney disease, and alterations in vitamin D metabolism
have traditionally been thought to play a pathogenic role
[4]. Monoclonal cell proliferation is found in nearly two
thirds of parathyroid glands removed from dialysis pa-
tients undergoing parathyroidectomy [5]. Although vita-
min D receptor (VDR) expression is generally reduced
in parathyroid tissue obtained from patients with ure-
mic SHPT, VDR expression is lower, and the degree
of parathyroid gland enlargement is greater in tissues
with a nodular rather than a diffuse histologic pattern of
hyperplasia [6]. Because vitamin D exerts antiprolifera-
tive effects in a variety of cell types in vitro, such findings
suggest that decreases in VDR expression, either alone
or together with reductions in circulating ligand concen-
trations, facilitate the process of parathyroid hyperplasia.
Recent observations challenge this view.
Mice that are homozygous for inactivating mutations
of the VDR develop all of the classic manifestations
of vitamin D deficiency, including hypocalcemia, osteo-
malacia, rachitic changes in growth plate cartilage, ele-
vated plasma PTH levels, and marked parathyroid gland
hyperplasia [7]. Hypocalcemia can be prevented, how-
ever, by feeding the animals a calcium-rich diet supple-
mented with lactose to promote passive intestinal calcium
absorption. This experimental maneuver completely pre-
vents the development of parathyroid gland hyperpla-
sia in tissues that are unable to respond to vitamin D
[8]. Such findings suggest that extracellular calcium ions,
rather than vitamin D, play a fundamental role in pre-
venting the development of parathyroid gland hyperpla-
sia, probably by signaling through the calcium-sensing
receptor (CaSR). Evidence of parathyroid gland hyper-
plasia in mice with inactivating mutations of the CaSR
further supports this view [9, 10].
Although recent management strategies have reduced
the need for surgical intervention to treat SHPT in pa-
tients undergoing long-term dialysis, the goals of pre-
venting parathyroid gland hyperplasia, retarding disease
progression, and controlling SHPT for extended periods
have not been realized. It is likely that new therapeutic
agents with the capacity to favorably affect the process of
parathyroid gland hyperplasia will be required to achieve
these objectives.
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